摘要
Venetoclax(维奈托克)是一种BCL-2选择性抑制剂,在急性髓系白血病(acute myeloid leukemia,AML)患者中具有良好的耐受性。近些年来,Venetocla x的使用愈加普遍,大部分AML患者对基于Venetocla x的联合用药方案反应良好。临床上一般将Venetocla x与低剂量阿糖胞苷或去甲基化药物联合使用,均取得了比单药治疗更高的缓解率,且患者耐受性良好。如今,靶向治疗药物发展迅速,Venetoclax联合各种靶向药物的临床试验正在进行中,希望可以指导AML的临床治疗。但Venetocla x疗效并不持久,极易产生耐药,进而复发。Venetocla x耐药机制错综复杂,尚未完全阐明,因此在Venetoclax的应用过程中应关注其耐药的产生。
Venetoclax is a selective inhibitor of BCL-2,which is well tolerated in acute myeloid leukemia(AML) patients.In recent years,the use of Venetoclax has become more common,and most AML patients have responded well to Venetoclax-based combination regimens.Clinically,Venetoclax is generally used in combination with lowdose cytarabine or demethylating drugs,and both have achieved a higher remission rate than single-agent therapy.and the patient is well tolerated.Nowadays,targeted therapy drugs are developing rapidly.The clinical trials of Venetoclax combined with various targeted drugs are underway,with the hope to guide the clinical treatment of AML.However,the curative effect of Venetoclax is not long-lasting,and it is easy to develop resistance and relapse.The resistance mechanism of Venetoclax is complicated and has not been fully clarified.Therefore,during the application of Venetoclax,attention should be paid to the emergence of drug resistance.
作者
王玉凰(综述)
李英花(审校)
WANG Yuhuang;LI Yinghua(Department of Hematology,First Affiliated Hospital of Harbin Medical University,Harbin 150000,China)
出处
《临床与病理杂志》
CAS
2021年第12期2980-2986,共7页
Journal of Clinical and Pathological Research